Radius Health (RDUS) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Radius Health Reports Second Quarter 2015 Financial and Operating Results
August 6, 2015 6:00 AM EDTManagement to host conference call today at 7:30 am EDT
WALTHAM, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, reported its financial results for the second quarter ended June 30, 2015, and provided recent corporate highlights. As of June 30, 2015, Radius had $224.0 million in cash, cash equivalents and marketable securities, and on July 28, 2015, raised approximately $323.8 million of net proceeds in a... More
Radius Health to Present at the 35th Annual Canaccord Genuity Growth Conference
August 5, 2015 8:52 PM EDTWALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annual Canaccord Genuity Growth... More
